EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation

Fumiya Wada iD, Junya Kanda iD, Kimimori Kamijo, Masashi Nishikubo, Satoshi Yoshioka, Takayuki Ishikawa, Yasunori Ueda, Takashi Akasaka, Yasuyuki Arai, Kiyotaka Izumi, Hirokazu Hirata, Takashi Ikeda und 16 weitere

Cell Transplantation · 2023

DOI: 10.1177/09636897231194497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Transplantation, 2023. Verfasst von Fumiya Wada und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Cord Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-host disease (GVHD) on outcomes after these transplants have not been fully elucidated. Therefore, we evaluated the effects of acute and chronic GVHD on transplant outcomes after PTCy-haplo transplants and compared them with CBT and MDT. We included a total of 914 adult patients with hematological malignancies in the Kyoto Stem Cell Transplantation Group registry who received PTCy-haplo (N = 120), CBT (N = 402), and MDT (N = 392), and achieved neutrophil engraftment. A multivariate analysis revealed that grade I–II acute GVHD improved of overall survival (OS) after PTCy-haplo [hazard ratio (HR) = 0.39, P = 0.018] and CBT (HR = 0.48, P < 0.001), but not after MDT (HR = 0.80, P = 0.267) compared with patients without acute GVHD. Grade I–II acute GVHD had a trend toward reducing the risk of nonrelapse mortality (NRM) after PTCy-haplo (HR = 0.13, P = 0.060) and this positive effect was significant after CBT (HR = 0.39, P = 0.003). A negative impact of grade III–IV acute GVHD on NRM was observed after CBT and MDT, but not after PTCy-haplo. Limited chronic GVHD had a positive impact on OS after CBT and MDT, but not after PTCy-haplo. In conclusion, mild acute GVHD improved outcomes after PTCy-haplo and CBT, and limited chronic GVHD improved outcomes after CBT and MDT. These data indicated that the effects of GVHD on transplant outcomes depended on transplant platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHematologic NeoplasmsBronchiolitis Obliterans SyndromeAdultHumansCyclophosphamideTransplantation ConditioningRetrospective Studies

Stichwörter der Autor:innen

acute graft-versus-host diseasechronic graft-versus-host diseasecord blood transplantationhaploidenticalhematological malignanciesposttransplant cyclophosphamide

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Department of Hematology/Oncology, Kurashiki Central Hospital, Okayama, Japan.
  • Department of Hematology, Tenri Hospital, Tenri, Japan.
  • Department of Hematology, Kansai Electric Power Hospital, Osaka, Japan.

ORCID-Profile: Fumiya Wada, Junya Kanda

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Wada, F., Kanda, J., Kamijo, K., Nishikubo, M., Yoshioka, S., Ishikawa, T., Ueda, Y., Akasaka, T., Arai, Y., Izumi, K., Hirata, H., Ikeda, T., Yonezawa, A., Anzai, N., Watanabe, M., Imada, K., Yago, K., Tamura, N., Itoh, M., …, & Takaori-Kondo, A. (2023). Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. Cell Transplantation. https://doi.org/10.1177/09636897231194497

Vancouver

Wada F, Kanda J, Kamijo K, Nishikubo M, Yoshioka S, Ishikawa T, et al. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. Cell Transplantation. 2023. doi:10.1177/09636897231194497

BibTeX
@article{Wada2023,
  author = {Wada, Fumiya and Kanda, Junya and Kamijo, Kimimori and Nishikubo, Masashi and Yoshioka, Satoshi and Ishikawa, Takayuki and Ueda, Yasunori and Akasaka, Takashi and Arai, Yasuyuki and Izumi, Kiyotaka and Hirata, Hirokazu and Ikeda, Takashi and Yonezawa, Akihito and Anzai, Naoyuki and Watanabe, Mitsumasa and Imada, Kazunori and Yago, Kazuhiro and Tamura, Naoki and Itoh, Mitsuru and Masuo, Yuki and Kunitomi, Akane and Takeoka, Tomoharu and Kitano, Toshiyuki and Arima, Nobuyoshi and Hishizawa, Masakatsu and Asagoe, Kohsuke and Kondo, Tadakazu and Takaori-Kondo, Akifumi},
  title = {Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation},
  journal = {Cell Transplantation},
  year = {2023},
  doi = {10.1177/09636897231194497}
}
Kostenlos starten →